Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Precision BioSciences, Inc. Common Stock

DTIL

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Last trade $7.00
Day change -$0.28 (-3.85%)
Day range $6.89 – $7.47
Volume 218,862
Market cap $278M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$277.88M
Price / earnings
—
Price / book
5.37×
Price / sales
8.12×
EV / sales
6.39×
EV / EBITDA
-4.61×

Profitability

Earnings per share
-$1.10
Return on assets
-34.79%
Return on equity
-80.88%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.43×
Current ratio
10.47×
Quick ratio
10.47×
Cash ratio
9.88×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
—

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DTIL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2026 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$34.2M$13K$18K$18K$29K$638K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$34.2M$13K$18K$18K$29K$638K
Selling, general and administrative$7.68M$6.77M$7.23M$7.33M$9.13M$9.13M$8.55M$9.58M
Research and development$12.75M$12.39M$14.46M$13.35M$12.77M$12.77M$13.59M$15.91M
Total operating expenses$20.43M$19.16M$21.7M$20.68M$21.9M$21.9M$22.14M$25.48M
Operating income-$20.43M-$19.16M$12.51M-$20.67M-$21.88M-$21.88M-$22.11M-$24.85M
Interest expense-$307K-$300K-$348K-$362K-$358K-$358K-$354K-$392K
Income before taxes-$7.59M-$32.65M$19.25M-$21.77M-$23.52M-$23.52M-$20.57M-$17.75M
Income taxes$0$0$0$0$0$0$0$0
Net income-$7.59M-$32.65M$20.13M-$21.77M-$23.52M-$23.52M-$20.57M-$17.75M
Net income attributable to common shareholders-$7.59M-$32.65M$20.13M-$21.77M-$23.52M-$23.52M-$20.57M-$17.75M
EBITDA-$20.43M-$19.16M$12.85M-$20.67M-$21.5M-$21.88M-$21.72M-$24.39M
Basic earnings per share-$0.28-$1.26$1.05-$1.84-$2.13-$2.13-$2.21-$2.21
Diluted earnings per share-$0.28-$1.26$1.05-$1.84-$2.13-$2.13-$2.21-$2.17

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

CPTx appoints Matt Kane as Chief Financial Officer

CPTx announced the appointment of Matt Kane as Chief Financial Officer. Kane brings extensive experience in gene editing and cell therapy, with a track record of raising over $500 million in equity financing and securing strategic partnerships valued at over $4 billion. He previously served as CEO of Celyad Oncology, Tune Therapeutics, and Precision Biosciences. Kane will lead CPTx's financing and partnering activities as the company advances its non-viral DNA-based in vivo CAR T therapies toward clinical studies.

GlobeNewswire Inc.

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.

GlobeNewswire Inc.

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

GlobeNewswire Inc.

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.

GlobeNewswire Inc.

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 14, 20241-for-30reverse split